Opendata, web and dolomites

SUMOblock

Blocking SUMO conjugation as drug discovery strategy.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "SUMOblock" data sheet

The following table provides information about the project.

Coordinator
CENTRE DE RECERCA EN AGRIGENOMICA CSIC-IRTA-UAB-UB 

Organization address
address: PARC DE RECERCA DE L UAB CAMPUS UAB EDIFICI CRAG BELLATERRA
city: CERDANYOLA DEL VALLES
postcode: 8193
website: www.cragenomica.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE DE RECERCA EN AGRIGENOMICA CSIC-IRTA-UAB-UB ES (CERDANYOLA DEL VALLES) coordinator 150˙000.00

Map

 Project objective

In eukaryotes, SUMO (Small Ubiquitin Modifier) conjugation to proteins is an essential process that regulates many aspects of cell biology. Defects in SUMO conjugation have been associated to cancer, neurodegenerative diseases and others, raising a great interest in developing novel drugs for inhibiting SUMO conjugation.

Specifically, recent reports have pointed to a high dependency on an active SUMO conjugation by Myc-overexpressing cancers. Consequently, SUMO conjugation has become a non-oncogene addiction target of special relevance since the oncogenic Myc is nondruggable. Based on the results obtained by our group, we have developed a novel assay for identifying efficient SUMO conjugation inhibitors, which could lead to the identification of novel therapeutic drugs.

The main outcome that we expect to obtain from this project is the identification of a SUMOylation inhibitor that will be patent protected. Initial steps towards the valorization of the identified product will be taken, and available commercialization opportunities will be carefully analyzed for entering into the next steps of drug development, including preclinical and clinical studies.

The fact that SUMOylation may be a key element in almost 70% of cancer types due to its involvement in the Myc pathway makes the search for hit drug candidates an enterprise worth taking, which could benefit millions of people worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMOBLOCK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMOBLOCK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More  

FuncMAB (2019)

High-throughput single-cell phenotypic analysis of functional antibody repertoires

Read More  
lastchecktime (2022-10-07 2:16:50) correctly updated